Performance evaluation of the Simtomax® CoronaCheck rapid diagnostic test

Testing for SARS-CoV-2 antibodies remains a critical component of pandemic response strategies. While RT-PCR is the gold standard for active infection, serological testing provides insights into past exposure and immunity. Prior research has shown that rapid diagnostic tests (RDTs) can offer a practical alternative in resource-limited settings. However, the accuracy of these tests varies, especially in relation to the timing of sample collection after symptom onset. This gap motivated the need for a study to evaluate the Simtomax® CoronaCheck RDT specifically for its ability to detect IgG and IgM in plasma. No prior work had resolved the performance of this test in a high-prevalence context. Understanding its sensitivity and specificity is essential for guiding its use in clinical and public health settings. The study aimed to address these uncertainties by comparing the RDT to established methods like ECLIA and RT-PCR. This approach allows for a more accurate assessment of the test’s reliability in real-world conditions. The findings could inform decisions on where and how to deploy the test effectively.

This study aimed to assess the diagnostic accuracy of the Simtomax® CoronaCheck RDT for detecting SARS-CoV-2-specific IgG and IgM antibodies in plasma. The researchers focused on evaluating the test’s performance in a high-prevalence setting, where such tests may be most useful. They compared the RDT to RT-PCR and ECLIA to determine its sensitivity and specificity. The motivation for this work stemmed from the need for reliable, accessible serological testing in areas with limited laboratory infrastructure. The study also sought to determine how the test performs at different time points after symptom onset. By analyzing samples collected at various intervals, the researchers aimed to identify the optimal window for accurate detection. This information is crucial for guiding the practical application of the test in clinical and public health contexts. The study’s design allowed for a comprehensive evaluation of the RDT’s utility in real-world conditions.

The researchers evaluated the Simtomax® CoronaCheck RDT using 48 plasma samples that were RT-PCR positive for SARS-CoV-2 and 98 negative control samples. They compared the RDT results to those obtained from RT-PCR and the ECLIA Elecsys® Anti-SARS-CoV-2 total Ig assay. The study focused on measuring sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV). They analyzed the data to determine how the test performed at different time points after symptom onset. The researchers categorized samples based on the number of days post-symptoms (DPS) to assess temporal accuracy. They used statistical methods to calculate 95% confidence intervals for each performance metric. This approach allowed them to evaluate the test’s reliability in a high-prevalence setting. The study design ensured that the RDT’s performance could be compared to established diagnostic methods.

The Simtomax® CoronaCheck RDT demonstrated an overall sensitivity of 92% (95% CI: 79-97%) and a specificity of 97% (95% CI: 91-99%). The positive predictive value was 94% (95% CI: 81-98%), and the negative predictive value was 96% (95% CI: 89-99%). When considering only samples collected ≥15 days post-symptoms, the sensitivity improved to 98% (95% CI: 86-100%). The specificity remained at 97% (95% CI: 91-99%) in this subset. Two samples collected 180 days post-symptoms were still positive for IgG. These results indicate that the RDT performs well in detecting SARS-CoV-2 antibodies in plasma. The test’s accuracy is particularly strong when used in the 15 to 180-day window after symptom onset. The findings suggest that the RDT could be a reliable alternative in settings where routine serology testing is not available.

The Simtomax® CoronaCheck RDT showed high diagnostic accuracy for detecting SARS-CoV-2 IgG and IgM in plasma. The test’s sensitivity and specificity were comparable to established methods like ECLIA and RT-PCR. The study found that the RDT performs best when used in the 15 to 180-day window after symptom onset. The researchers propose that the test could be effectively used in high-prevalence settings where access to routine serology is limited. The findings suggest that the RDT is a practical option for antibody testing in such contexts. The test’s performance was particularly strong for IgG detection in samples collected up to 180 days post-symptoms. The authors suggest that the RDT may be a useful tool for monitoring past exposure in populations with limited laboratory resources. These conclusions are based on the study’s direct comparison of the RDT to RT-PCR and ECLIA.